tuberculosis - PRWeb Press Release Group http://www.prweb.com tuberculosis - Powered by PRWeb en xml@emediawire.com xml@emediawire.com 30 High Success Rate in Immunotherapy Trial of TB/HIV 'Deadly Duo' Infection http://www.prweb.com/releases/2009/07/prweb2653584.htm Adjunct immunotherapy with herbal supplement Immunoxel (Dzherelo) combined with first-line TB drugs resulted in clearance of Mycobacterium tuberculosis in sputum cultures: 67% vs. 16% patients treated with TB drugs alone, with average time to negative culture 4 and 6 months respectively. Immunoxel, given at 50 drops twice-per-day dose, resulted in higher healing rate of cavitary/miliary involvements - i.e. 60%/84% in Immunoxel patients and 25%/46% in ATT alone patients. Immunotherapeutic intervention produced significant positive changes in body weight: 5.8±2.6 kg gain vs. 0.6±2.4 kg loss in ATT only patients. The incidence of opportunistic infections reduced in ATT + Immunoxel patients - 3 episodes vs. 12 episodes in ATT alone patients. This study appeared in British journal Immunotherapy (July 2009, Vol. 1, No. 4, Pages 549-556 - see link to the abstract at - http://www.futuremedicine.com/doi/abs/10.2217/imt.09.25 (PRWeb Jul 19, 2009)

Read the full story at http://www.prweb.com/releases/2009/07/prweb2653584.htm

]]> Sun, 19 Jul 2009 07:00:00 GMT http://www.prweb.com/releases/2009/07/prweb2653584.htm Faster TB Healing by Combining Dzherelo (Immunoxel) with TB Drugs http://www.prweb.com/releases/2009/05/prweb2470834.htm The clinical study in 75 first-diagnosed TB patients published in the monthly journal of journal of the European Society of Clinical Microbiology and Infectious Diseases reveals that when standard, first-line TB drugs are combined with Dzherelo (Imunoxel), the combination can produce significant clinical and radiological improvements and clearance of M. tuberculosis at higher rate than in patients on TB drugs alone. Biochemistry and hematological analysis of blood samples support favorable adjunctive effect of Dzherelo, which has not shown any adverse effects throughout the study duration. (PRWeb May 29, 2009)

Read the full story at http://www.prweb.com/releases/2009/05/prweb2470834.htm

]]> Fri, 29 May 2009 07:00:00 GMT http://www.prweb.com/releases/2009/05/prweb2470834.htm Ekomed presents at the 5th Congress of the International Union Against Tuberculosis and Lung Disease http://www.prweb.com/releases/2009/05/prweb2465964.htm Promising findings from Ukrainian XDR-TB immunotherapy trial will be presented at the 5th conference of the International Union Against Tuberculosis and Lung Disease (The Union), Europe Region, held in Dubrovnik, Croatia, between 27 and 30 May 2009. During conference all fields of tuberculosis and respiratory medicine will be covered by world renowned experts. The Immunoxel clinical study demonstrated the drastic difference between standard TB drugs alone versus TB drugs supplemented with immune adjuvant regimen consisting of Ekomed phytoconcentrates. (PRWeb May 28, 2009)

Read the full story at http://www.prweb.com/releases/2009/05/prweb2465964.htm

]]> Thu, 28 May 2009 07:00:00 GMT http://www.prweb.com/releases/2009/05/prweb2465964.htm Sales of Ekomed Botanical Immunomodulator Started in Asia http://www.prweb.com/releases/2009/04/prweb2345154.htm Ekomed LLC announces that it has sold and shipped the first order of its phyto-concentrate Dzherelo (Immunoxel) for sale outside the Ukraine. This first shipment of 5,000 units was delivered to Mongolia - one of the highest TB burden countries in Western Pacific region and a second order for 10,000 units has already been received. (PRWeb Apr 23, 2009)

Read the full story at http://www.prweb.com/releases/2009/04/prweb2345154.htm

]]> Thu, 23 Apr 2009 07:00:00 GMT http://www.prweb.com/releases/2009/04/prweb2345154.htm